Chemotherapy, Patient Care and Seminar - Pharmacy Technician Pulse

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Chemotherapy

Patient Care

Seminar

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

Pharmacy Times

JUNE 10, 2025

1 "[Meloxicam injection] demonstrates our commitment to improving patient care by providing an alternate dosage form for pain management," Ron Scarboro, chief executive officer at Azurity Pharmaceuticals, said in a press release. Seminars in Arthritis and Rheumatism. PR Newswire. June 10, 2025. Accessed June 10, 2025.

FDA

FDA HIV Treatment and Prevention Agents Compounding Pharmacies Hospitals

The evolution of durvalumab in NSCLC care

Hospital Pharmacy Europe

NOVEMBER 4, 2024

Durvalumab is ‘promising step forward’ The latest approval from the MHRA is based on positive data from the AEGEAN Phase III trial in rNSCLC , which showed that durvalumab-based treatment before and after surgery reduced the risk of recurrence, progression events or death by 32% versus neoadjuvant chemotherapy alone.

Chemotherapy

Chemotherapy Patient Care Clinic Management Hospitals

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

The evolution of durvalumab in NSCLC care

Stay Connected